1. Introduction {#sec1-ijms-19-02473}
===============

Ovarian carcinomas of mucinous histology (MOC) are an uncommon type of ovarian cancer characterized by intracellular mucin deposits and relatively favorable prognosis when diagnosed at early stage \[[@B1-ijms-19-02473]\]. Few epidemiologic risk factors are known for these cancers, and the standard risk factors for other types of ovarian cancer do not seem to apply \[[@B2-ijms-19-02473]\]. Increased risk has been associated with current or recent smoking, a higher number of pack years of smoking \[[@B3-ijms-19-02473],[@B4-ijms-19-02473]\], and with increased body mass index \[[@B5-ijms-19-02473]\]. Recently, we reported the first genome-wide significant-susceptibility alleles for MOC at 2q13, 2q31.1, and 19q13.2 \[[@B6-ijms-19-02473]\], and at 3q22.3 and 9q31.1 \[[@B7-ijms-19-02473]\].

Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis in both normal and tumor cells. It catalyzes the transformation of dUMP to dTMP and is the only de novo source of thymidylate for pyrimidine biosynthesis \[[@B8-ijms-19-02473]\]. Consequently, it is an important chemotherapy target. We previously found an association between the rs495139 single-nucleotide polymorphism (SNP) and increased risk of MOC (odds ratio (OR) = 1.91; 95% confidence interval (CI) = 1.10--3.31; *p* = 0.02; N = 80 MOC cases) (unpublished) in an earlier genotyping project \[[@B9-ijms-19-02473]\] that we subsequently confirmed (hereto referred to as "discovery" sample) (OR = 1.32; 95% CI = 1.07--1.62; *p* = 0.02; N = 354 MOC cases) \[[@B10-ijms-19-02473]\]. This SNP is located downstream of the 3′ untranslated region (UTR) of *TYMS* (Entrez Gene ID 7298) and situated intronic to the enolase superfamily member 1 (*ENOSF1*, Entrez Gene ID 55556) gene on chromosome 18. *ENOSF1* encodes an antisense transcript that downregulates TYMS gene expression \[[@B11-ijms-19-02473],[@B12-ijms-19-02473],[@B13-ijms-19-02473]\]. We hypothesized that genetic polymorphisms could perturb the TYMS mRNA-antisense mRNA autoregulatory complex by either increasing TYMS or decreasing ENOSF1 gene expression to promote uncontrolled DNA synthesis and tumor growth. Given the SNP's potential functional role to regulate TYMS expression and because TYMS is an important chemotherapy target, our objective was to replicate the genetic association from our discovery sample \[[@B10-ijms-19-02473]\] using a very large independent sample of MOC from participating studies in the Ovarian Cancer Association Consortium (OCAC) that were genotyped as part of the international Collaborative Oncology Gene-environment Study (iCOGS).

2. Results {#sec2-ijms-19-02473}
==========

2.1. Association Testing {#sec2dot1-ijms-19-02473}
------------------------

There were 667 MOC cases and 15,941 controls in the independent iCOGS sample, but ORs could not be estimated for four individual studies, resulting in 665 MOC cases and 15,256 controls evaluated using the meta-analysis approach. The association between rs495139 and MOC in the iCOGS sample was not significant (OR = 1.09; 95% CI = 0.97--1.22; *p* = 0.15; N = 665 cases) ([Table 1](#ijms-19-02473-t001){ref-type="table"}). The meta-analysis combining the iCOGS sample with the discovery sample \[[@B10-ijms-19-02473]\] suggested an increased risk (OR = 1.13; 95% CI = 1.03--1.24; *p* = 0.01; N = 1019 cases) ([Table 1](#ijms-19-02473-t001){ref-type="table"}). The between-group heterogeneity was low to moderate for the discovery studies (*I*^2^ = 37.6), and low for the iCOGS studies (*I*^2^ = 0) and for all studies in the meta-analysis (*I*^2^ = 14.9) ([Figure 1](#ijms-19-02473-f001){ref-type="fig"}). The ORs did not differ appreciably using a pooled-analysis approach that combined all cases and controls from the discovery \[[@B10-ijms-19-02473]\] and iCOGS samples into a single dataset (OR = 1.12; 95% CI = 1.02--1.22; *p* = 0.02; N = 1021 cases) ([Table 1](#ijms-19-02473-t001){ref-type="table"}). Thus, we proceeded with additional analyses using the pooled data. rs495139 was not associated with ovarian cancer overall or with the other histologic types ([Table 1](#ijms-19-02473-t001){ref-type="table"}, *p* = 0.05 for tumor heterogeneity, 4 df). Because molecular evidence suggests that many invasive MOC evolve along a multistep model of progression from benign to atypical proliferative (borderline) epithelium \[[@B1-ijms-19-02473]\] similar to colorectal cancer \[[@B14-ijms-19-02473]\], we evaluated the association between rs495139 and borderline MOC only (OR = 0.97; 95% CI = 0.86--1.09; *p* = 0.59, N = 621) and with combined borderline and invasive MOC (OR = 1.06; 95% CI = 0.99--1.14; *p* = 0.11, N = 1642 cases). The weakened associations suggested the SNP might contribute only to the invasive phenotype. Women diagnosed with MOC had an earlier age at diagnosis (median age = 54 years) than women with the more common serous histology (median age = 60 years). To assess whether or not potentially different age distributions between MOC cases and controls influenced ORs, we matched each case to within 5-year age categories to three controls, where possible, and performed an age-stratified logistic regression. The OR was slightly larger (seven cases could not be matched due to young age of diagnosis): OR = 1.16 (95% CI = 1.04--1.28; *p* = 0.006; N = 1013 cases and 3014 controls) when the median age was similar (54 years for cases and 54.7 years for controls).

2.2. Expression Quantitative Trait Locus (eQTL) Analysis {#sec2dot2-ijms-19-02473}
--------------------------------------------------------

We tested for eQTL association between rs495139 genotypes and gene expression in normal tissues in the Genotype Tissue Expression (GTEx) project. The most significant eQTL was with increased ENOSF1 mRNA expression in normal esophagus mucosa (*r* = 0.51, *p* = 1.7 × 10^−28^) ([Figures S1 and S2](#app1-ijms-19-02473){ref-type="app"}). There was no reported association with TYMS mRNA expression in esophageal mucosa. In 316 women with ovarian cancer (five were MOC tumors), eQTL analysis between germline genotypes of rs495139 and tumor gene expression showed positive associations for two probes targeting ENOSF1 (P15906: beta = 0.17, *p* = 0.03, and P4503: beta = 0.15, *p* = 0.05) but not with the probe targeting TYMS (P50096: beta = 0.12, *p* = 0.12) ([Table S1](#app1-ijms-19-02473){ref-type="app"}). Among the five MOC tumors, we observed positive eQTL associations with one probe targeting ENOSF1 (P4503: beta = 0.87, *p* = 0.32) but not the other (P15906: beta = 0.08, *p* = 0.94) and an inverse eQTL association with the probe targeting TYMS (P50096: beta = −0.70, *p* = 0.45) but none were statistically significant given the small sample size.

3. Discussion {#sec3-ijms-19-02473}
=============

We previously observed a statistically significant risk association of rs495139 \[[@B10-ijms-19-02473]\], which was not replicated by this larger analysis of MOC. Combining the two independent datasets of 1019 MOC samples suggested a weakly positive association between rs495139 and risk of MOC, particularly in age-matched analysis. The association observed from the combined analysis was attenuated with the inclusion of borderline cases.

Few genetic risk factors for MOC are known. We previously published results from two genome-wide association studies (GWAS) reporting five susceptibility variants for MOC at 2q13, 2q31.1, 19q13.2 \[[@B6-ijms-19-02473]\], 3q22.3, and 9q31.1 \[[@B7-ijms-19-02473]\]. The likelihood that the candidate SNP rs495139 is a genetic risk factor for MOC is small. Since the time of preparing this manuscript, we conducted a third, larger GWAS of ovarian cancer \[[@B7-ijms-19-02473]\], which included many of the participants in the current report. Results from that GWAS also do not support significant associations between rs495139 and invasive MOC (OR = 0.93; 95% CI = 0.86--1.01; *p* = 0.07, 1417 cases) or combined borderline and invasive MOC (OR = 0.97; 95% CI = 0.91--1.03; *p* = 0.29, 2566 cases). Our results suggest the previously published significant association \[[@B10-ijms-19-02473]\] was likely driven by heterogeneity from a few studies with extreme ORs and that balanced age matching between MOC cases and controls might reduce some bias. A strong functional influence of rs495139 on increased ENOSF1 gene expression was found in GTEx normal gastrointestinal tissues and, in particular, esophageal mucosa. This is interesting because the origin of normal tissue from which MOC arises is unclear but may be similar to the mucosa of the gastrointestinal system \[[@B1-ijms-19-02473],[@B15-ijms-19-02473]\]. For example, small array-based studies (N = 3 to 9) of MOC relate them more closely to colonic epithelium or colorectal cancers than to normal ovarian surface epithelium \[[@B15-ijms-19-02473],[@B16-ijms-19-02473]\]. Further, some MOC may arise from a morphologically analogous transition observed in gastroesophageal adenocarcinoma. The metaplasia seen in MOC is a change in cell type from a monolayer of normal nondescript, poorly differentiated mesothelial cells \[[@B17-ijms-19-02473]\] to a single layer of tall, columnar epithelial cells with mucin-containing cytoplasm \[[@B18-ijms-19-02473]\]. This is analogous to the metaplasia seen in the development of Barrett's esophagus, the precursor lesion to gastroesophageal adenocarcinoma, where there is a change in cell type from a flat squamous cell layer to columnar-like epithelium with visible mucus \[[@B19-ijms-19-02473]\]. We also observed a nonsignificant but positive eQTL association between rs495139 and a probe for ENOSF1 mRNA in MOC, as well as an inverse eQTL association between rs495139 and TYMS mRNA in MOC tumors, which contradicts our hypothesis that rs495139 might decrease ENOSF1 antisense mRNA to possibly increase TYMS mRNA availability for DNA synthesis and tumor growth. The small number of MOC tumors in this eQTL analysis precluded any definitive interpretation of results. Given that TYMS is a chemotherapy target, an rs495139-associated increase in ENOSF1 and decrease in TYMS expression might suggest a favorable tumor profile for patient survival.

This investigation was strengthened by including large numbers of women with MOC that contributed individual genotype data in iCOGS and by the ability to conduct an age-matched analysis to control for differences in the distribution of age among cases and controls, which could potentially bias associations. A further advantage was our centralized genotyping and rigorous quality-control standards. We were also able to query data in silico as well as in women with corresponding germline SNP and tumor gene expression data from the Mayo Clinic in order to provide contextual information on potential functional influences between genotypes and tumor gene expression.

In summary, the evidence in this study to support a role of rs495139 in the *TYMS-ENOSF1* region as a genetic risk factor for MOC is weak and suggests that any true effect is likely to be small.

4. Materials and Methods {#sec4-ijms-19-02473}
========================

4.1. Study Subjects and Genotyping {#sec4dot1-ijms-19-02473}
----------------------------------

Subjects (*n* = 47,630) represented multiple individual studies participating in the OCAC \[[@B20-ijms-19-02473]\]. Informed consent was obtained in individual studies and local human research investigation committees approved each study. *TYMS-ENOSF1* rs495139 was genotyped on an Illumina Infinium custom iSelect BeadChip developed for the iCOGS (Beadchip) \[[@B21-ijms-19-02473]\]. Among 44,634 subjects whose DNA passed centralized genotyping quality-control criteria \[[@B20-ijms-19-02473]\], the call rate for rs495139 was 99.98%. We restricted the analysis to subjects with European ancestry and invasive tumors, leaving 37,792 eligible subjects. Of these, the effect allele frequency (EAF) among 23,444 controls was 0.41 and no departure from Hardy--Weinberg equilibrium was seen (*p* = 0.32).

To obtain the independent sample (referred to as the "iCOGS" sample), we excluded genotypes in iCOGS from women who were in our earlier analysis \[[@B10-ijms-19-02473]\] (referred to as the "discovery" sample). Individual-level genotypes were available on 10,019 invasive ovarian cancer cases (667 with invasive MOC) and 15,941 controls from 31 studies in iCOGS for replication analysis. We also re-evaluated the rs495139 association by combining genotypes from the iCOGS sample with the discovery sample (4981 invasive ovarian cancer cases, of which 354 were invasive MOC, and 8410 controls from 14 OCAC studies) \[[@B10-ijms-19-02473]\], resulting in a total of 15,000 invasive ovarian cancer cases (1021 with invasive MOC) and 24,351 controls ([Table S2](#app1-ijms-19-02473){ref-type="app"}). This larger sample allowed additional subset analyses to be performed.

4.2. In Silico and eQTL Analysis {#sec4dot2-ijms-19-02473}
--------------------------------

We used the GTEx project portal (V7 data release, 18 September 2017) \[[@B22-ijms-19-02473]\] for in silico eQTL analysis between rs495139 and TYMS and ENOSF1 gene expression in 10,294 eQTL normal tissues representing over 50 different tissue types. We evaluated eQTL between rs495139 genotypes from lymphocytes with gene expression from patient-matched tumors among 316 women with ovarian cancer (including five MOC tumors) from the Mayo Clinic. Gene expression was assessed using a 4 × 44 K Agilent array (Agilent Technologies, Santa Clara, CA, USA) and measured as log~2~(tumor/reference) probe intensity signals as described previously \[[@B23-ijms-19-02473]\] based on a mixed tumor cell-type reference of 104 tumor samples, including papillary serous (*n* = 67), endometrioid (*n* = 5), mucinous (*n* = 3), clear cell (*n* = 3), malignant mixed Müllerian tumor (*n* = 5), goblet cell (*n* = 1), squamous (*n* = 1), transitional cell (*n* = 1), benign (*n* = 4), normal (*n* = 7), and unknown epithelial (*n* = 7). Analyses included one Agilent probe for TYMS (P50096) and two probes for ENOSF1 (P15906 and P4503).

4.3. Statistical Analysis {#sec4dot3-ijms-19-02473}
-------------------------

ORs and 95% CIs were estimated using unconditional logistic regression assuming an ordinal (log-additive) genetic model and adjusting for study and for the first five eigenvalues from principal components analysis to account for substrata of European ancestry \[[@B20-ijms-19-02473]\]. Using fixed-effects meta-analysis, we combined study-specific effect estimates from our previous report \[[@B10-ijms-19-02473]\] with study-specific effect estimates from unique iCOGS subjects using the inverse-variance method to weight the overall summary OR. The degree of statistical heterogeneity between studies was estimated by *I*^2^, the between-group variance \[[@B24-ijms-19-02473]\]. Studies with statistically homogeneous ORs yield an *I*^2^ value of zero. ORs were derived for ovarian cancers overall and simultaneously for the different histologic types (serous, mucinous, endometrioid, and clear cell) using polytomous logistic regression. Statistical heterogeneity of the SNP-ovarian carcinoma histology associations was tested using the type 3 analysis of effects with 4 degrees of freedom \[[@B25-ijms-19-02473]\]. Van der Waerden rank transformation was applied to tumor gene expression values from the Agilent array, adjusting for age in linear regression and treating the number of variant alleles carried as ordinal on the log-additive scale. Statistical tests were two-sided and implemented with SAS version 9 (SAS Institute, Cary, NC, USA). Meta-analysis was performed with Stata/SE (version 13.1, StataCorp, College Station, TX, USA).
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Deoxythymidine monophosphate

dUMP

Deoxyuridine monophosphate

ENOSF1

Enolase superfamily member 1

eQTL

Expression Quantitative Trait Locus

GTEx

Genotype Tissue Expression project

iCOGS

international Collaborative Oncology Gene-environment Study

MOC

Mucinous ovarian carcinoma

mRNA

Messenger ribonucleic acid

OCAC

Ovarian Cancer Association Consortium

SNP

Single nucleotide polymorphism

TYMS

Thymidylate synthase

UTR

Untranslated region

![Forest plot of the study-specific (filled diamonds) and pooled (open diamonds) odds ratios and 95% confidence intervals (solid horizontal lines) for the association between rs495139 and risk of MOC under the ordinal genetic risk model in the discovery and iCOGs samples. The total sample size in the meta-analysis is 1019 MOC cases and 23,666 controls of European ancestry. Dashed vertical line represents overall summary estimate--odds ratio. Individual study estimates are adjusted for ancestry and pooled estimates are adjusted for ancestry and study. See [Table 1](#ijms-19-02473-t001){ref-type="table"} footnote for details regarding sample size.](ijms-19-02473-g001){#ijms-19-02473-f001}
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###### 

Associations ^1^ between rs495139 and ovarian carcinoma among European subjects.

  Study Sample and Tumor Histology            Analysis Method   Cases, N   Controls, N   OR     95% CI       *p*-Value
  ------------------------------------------- ----------------- ---------- ------------- ------ ------------ -----------
  **iCOGS sample**                                                                                           
  Mucinous invasive only                      Meta-analysis     665 ^2^    15,256 ^2^    1.09   0.97--1.22   0.16
  **Discovery + iCOGS samples**                                                                              
  Mucinous invasive only                      Meta-analysis     1019 ^2^   23,666 ^2^    1.13   1.03--1.24   0.01
  All invasive tumors ^3^                     Pooled            15,000     24,351        1.00   0.97--1.03   0.84
  Mucinous invasive only                      Pooled            1021 ^2^   24,351        1.12   1.02--1.22   0.02
  Mucinous borderline                         Pooled            621        24,351        0.97   0.86--1.09   0.59
  Mucinous invasive and borderline combined   Pooled            1642       24,351        1.06   0.99--1.14   0.11
  Serous invasive                             Pooled            8889       24,351        1.01   0.98--1.05   0.53
  Endometrioid invasive                       Pooled            2164       24,351        0.97   0.91--1.04   0.40
  Clear cell invasive                         Pooled            1046       24,351        0.93   0.85--1.02   0.11

iCOGS, International Collaborative Oncology Gene-environment Study. ^1^ Studies in the meta-analysis were restricted to non-Hispanic whites (Discovery set), as in the original report \[[@B10-ijms-19-02473]\], or adjusted for European ancestry using principal components analysis (iCOGS). Studies in the pooled analysis were also adjusted for study set. ^2^ Two studies (HAW and STA) in iCOGS each contributed one mucinous ovarian carcinoma (MOC) case and two studies (NHS and MSK) did not contribute any MOC cases in iCOGS; therefore, odds ratios could not be calculated for these four studies and these subjects (HAW: 1 MOC case, 17 controls; STA: 1 MOC case, 6 controls; NHS: 0 MOC cases, 69 controls; MSK: 0 MOC cases, 593 controls) were dropped from the meta-analysis but were retained in the pooled analysis. ^3^ Includes invasive tumors with the following histology: serous; mucinous; endometrioid; clear cell; mixed cell; other specified epithelial ovarian cancer; undifferentiated or poorly differentiated epithelial; and unknown histology but known to be epithelial.
